KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Other financing activities (2016 - 2025)

Quest Diagnostics (DGX) has disclosed Other financing activities for 17 consecutive years, with $100.0 million as the latest value for Q4 2025.

  • Quarterly Other financing activities rose 75.44% to $100.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.0 million through Dec 2025, up 85.71% year-over-year, with the annual reading at $39.0 million for FY2025, 85.71% up from the prior year.
  • Other financing activities hit $100.0 million in Q4 2025 for Quest Diagnostics, up from -$11.0 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $100.0 million in Q4 2025 to a low of -$61.0 million in Q1 2025.
  • Historically, Other financing activities has averaged -$157894.7 across 5 years, with a median of $3.0 million in 2024.
  • Biggest five-year swings in Other financing activities: crashed 1075.0% in 2021 and later surged 244.44% in 2023.
  • Year by year, Other financing activities stood at $21.0 million in 2021, then plummeted by 195.24% to -$20.0 million in 2022, then surged by 190.0% to $18.0 million in 2023, then soared by 216.67% to $57.0 million in 2024, then soared by 75.44% to $100.0 million in 2025.
  • Business Quant data shows Other financing activities for DGX at $100.0 million in Q4 2025, -$11.0 million in Q3 2025, and $11.0 million in Q2 2025.